PHASE II, OPEN-LABEL STUDY TO ESTIMATE THE OVERALL RESPONSE RATES OF OLAPARIB IN SUBJECTS WITH RECURRENT/PROGRESSIVE IDH1/2-MUTANT SOLID TUMORS IN 3 COHORTS (GLIOMA, CHOLANGIOCARCINOMA, AND OTHER SOLID MALIGNANT TUMORS).

PI: Patricia LoRusso, DO
Professor of Medicine; Associate Director of Experimental Therapeutics
Yale Cancer Center

Close Menu